Orforglipron or Foundayo (the brand name by Eli Lilly) was approved by the MHRA on 10 August 2026, making the UK the first country in Europe to license this once-daily oral GLP-1 tablet.

We’ve written this article to tell you everything you need to know before starting or even considering starting it: how it actually works in your body, the step-by-step dosing schedule, what side effects are most common, the safety warnings you should know, and what the clinical trials showed.

Just in case you’re new to Orforglipron (Foundayo), we suggest you start here: what is orforglipron (Foundayo)? →

And if you’re familiar but want to compare it with other existing options, here: Foundayo vs Mounjaro vs the Wegovy pill →

How Does Orforglipron (Foundayo) Work?

GLP-1 Receptor Agonism, Simply Explained

GLP-1 is a gut hormone that your body releases to tell your brain when it’s full after eating. It slows down how quickly your stomach empties, and helps your body regulate blood sugar. Under normal circumstances, it breaks down within a few minutes.

Orforglipron is a synthetic version of this GLP-1 hormone, but designed to last throughout the day rather than minutes. The result: your appetite comes down, the persistent background noise of hunger and food craving quietens, food moves through your stomach more slowly so you stay full for longer, and your body's blood sugar response becomes more stable.

These effects are not independent, but rather reinforce each other, and together they alter your biology in a way that makes losing weight comparatively easy; not by forcing restriction but by removing the hormonal signals that drive overconsumption.

More on how GLP-1 medicines affect women specifically: peptides for weight loss: what they are and what’s legal in the UK →

Why It's Called a Non-Peptide or Small Molecule GLP-1

We’ve covered this in our introductory article about Orforglipron.

Wegovy and Mounjaro are peptides, meaning they are built from amino acids, just like proteins. Your stomach breaks the proteins down when swallowed. This is why Wegovy and Mounjaro were introduced as injections first. Then came the Wegovy Pill, also a peptide, but it contained a special carrier compound called SNAC. It basically helped smuggle the peptides through the stomach wall during a narrow absorption window, which is why it requires an empty stomach and a 30-minute fast.

Orforglipron is not a peptide. It is designed as a small chemical molecule that can survive stomach acid without any special carrier and absorb reliably regardless of food intake or timing. This is why you can take orforglipron with your morning coffee, your dinner, or before bed, and it will work the same way each time. Note - You must avoid grapefruit juice because it can dangerously alter how your body processes the medication.

This chemistry distinction gives Orforglipron a significant edge over every other GLP-1 medicine currently licensed in the UK.

Foundayo Dosing Schedule

Orforglipron is a once daily tablet, just like the Wegovy pill. The dose starts very low and increases gradually over several months. This is not because the medication takes months to work. It is to protect you from the GI side effects (nausea, constipation, loose stools) that most people experience early on are dose-dependent. The escalation schedule gives your body time to adjust to each level before going higher.

The Six-Step Titration Schedule

The minimum time to reach the maximum dose of 17.2 mg is five months. It is possible that you may find your maintenance dose before reaching 17.2mg. The schedule is flexible above the 5.5mg step. There is no requirement to reach the maximum dose. The right dose is the one that works for you with side effects you can manage.

Missed Doses

If you miss a dose for any reason, just skip it and take it as per your schedule the next day. Do not take two tablets in one day to make up for it. If you miss seven or more consecutive days, contact your prescriber before restarting, as re-titration at a lower dose may be needed to avoid returning side effects.

How the Dosing Schedule Compares With Other GLP-1 Medicines

For comparison, Mounjaro's escalation schedule runs from 2.5mg to 15mg over a similar minimum timeframe of 5 months. The Wegovy injection starts at 0.25mg weekly and reaches its maintenance dose of 2.4mg at week 17.

The thing to note here is that these are different molecules measured in different units. They are not to be numerically compared directly. The principle, however, remains the same: slow is safe.

See all current GLP-1 options at SheMed: treatment plans →

‍

Foundayo Side Effects

Common Side Effects

The frequently reported side effects of orforglipron are similar to those found with other GLP-1 medicines. They are mostly gastrointestinal, most pronounced during the early weeks of each new dose level, and typically ease as your body adjusts.

• Nausea: the most common side effect across all GLP-1 medicines. You may feel it the most in the first days to weeks at each new dose. Eating smaller meals, avoiding fatty or very rich foods, and staying hydrated helps significantly.
• Constipation: GLP-1 medicines slow gastric emptying, which can slow your whole digestive system. Adequate hydration, fibre intake, and regular movement are the most effective counters.
• Diarrhoea: less common than constipation but reported by some women, particularly at higher doses or during escalation.
• Vomiting: less common than nausea but can occur, particularly if your eating habits haven’t adjusted alongside the slower gastric emptying.
• Indigestion: reported in ATTAIN-1 at a higher rate than placebo. Smaller portions and eating slowly can reduce this significantly.
• Decreased appetite: more of an intended effect rather than a side effect, but some women find the degree of appetite reduction striking in the early weeks.

In the ACHIEVE-3 head-to-head trial that compares orforglipron (Foundayo) with oral semaglutide (Wegovy), treatment discontinuation rates due to adverse events were 8.7% for the 12mg dose and 9.7% for the 36mg dose of orforglipron, compared with 4.5% and 4.9% for oral semaglutide at equivalent doses.

This means that the side effects are real and some women do stop as a result, but the majority continue through the adjustment period.

The Boxed Warning: Thyroid C-Cell Tumours

While Orforglipron looks like the best option for most women, there are some who should be avoiding it.

Who Should Not Take Orforglipron

• Personal or family history of medullary thyroid carcinoma
• Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Pregnancy: may cause fetal harm. Stop at least two months before attempting conception
• Breastfeeding: not recommended, as it is not known whether orforglipron passes into breast milk
• Severe gastrointestinal disease or conditions that significantly affect gastric motility
• History of pancreatitis: disclose to your prescriber before starting

This is not an exhaustive list. A full clinical assessment, including blood testing, is required before any GLP-1 medicine is prescribed. Choose a prescriber that does it for you before suggesting anything.

Foundayo Clinical Trial Data

The ATTAIN Programme

Orforglipron’s MHRA approval is based primarily on data from the ATTAIN Phase 3 clinical trial programme. It is a series of large randomised controlled trials comparing orforglipron with placebo across different patient populations.

What the Weight Loss Studies Found

• ATTAIN-1 (adults without type 2 diabetes): at the highest dose over 72 weeks, participants lost an average of 12.4% of body weight. 59.6% lost at least 10% and 39.6% lost at least 15%. Significant improvements were also seen in waist circumference, blood pressure, and cholesterol. Among participants with prediabetes at baseline, up to 91% achieved near-normal blood sugar levels compared with 42% on placebo.
• ATTAIN-2 (adults with type 2 diabetes): average weight loss of 10.5% at 72 weeks at the highest dose, with HbA1c reduced by 1.8 percentage points.
• ATTAIN-MAINTAIN: this study included people who had previously taken injectable GLP-1 medicines and switched to orforglipron. It found that orforglipron maintained approximately 74.7% of the weight reduction previously achieved on the injectable, suggesting it can be a practical oral continuation option after injectables.

Where Did Foundayo Come From?

Orforglipron was originally discovered by Chugai Pharmaceutical, a Japanese pharmaceutical company, as part of their research into non-peptide GLP-1 receptor agonists. The compound’s unique ability to activate GLP-1 receptors without being a peptide molecule brought attention to it. It opened the door to oral delivery without the constraints that peptide GLP-1s face.

Eli Lilly subsequently in-licensed orforglipron from Chugai, conducted the full Phase 3 clinical development programme, and introduced to the market with the brand name Foundayo. The US FDA approved it on 1 April 2026, and the MHRA approved it on 10 August 2026, making the UK the first country in Europe to authorise it.

‍

Feel like knowing more about Foundayo? Keep reading!

Orforglipron (Foundayo) in the UK: Availability, Price and NHS Access →

What Is Orforglipron (Foundayo)? The New Oral GLP-1 Weight Loss Pill Explained →

Foundayo vs Mounjaro vs the Wegovy pill →

‍

Frequently Asked Questions

What is orforglipron’s generic name?

Orforglipron is the International Nonproprietary Name (INN) and the generic name of the drug. Foundayo is the brand name used by its founder Eli Lilly in the US and UK.

What is the brand name for orforglipron?

Foundayo is the brand name given by Eli Lilly to Orforglipron. The drug was approved under this name by the FDA on 1 April 2026 and by the MHRA on 10 August 2026. Foundayo and orforglipron are exactly the same medicine.

How long does orforglipron stay in your system?

Orforglipron has a half-life of approximately 14 to 19 hours, which is why once-daily dosing maintains consistent blood levels throughout the day. After stopping the medicine, it clears your system within a few days, unlike injectable semaglutide which has a half-life of approximately seven days. The shorter half-life means if you miss a day, the drop in drug levels is faster than with weekly injectables.

How is orforglipron taken?

Once daily as a tablet, at any time of day, with or without food, with any amount of water. No empty stomach requirement. No timing restriction. No specific water volume. You start at 0.8mg and escalate according to your prescriber’s guidance, spending at least 30 days at each dose level.

What is the most common side effect of orforglipron?

Nausea is the most commonly reported side effect, consistent with all GLP-1 based medicines. It is most prominent in the early weeks of each new dose level and typically eases as your body adjusts. Eating smaller portions, avoiding rich or very fatty meals, and staying well hydrated helps significantly.

How do I get orforglipron in the UK?

Orforglipron (Foundayo) received MHRA approval on 10 August 2026 and can be legally prescribed in the UK through private prescription. Physical availability depends on Eli Lilly’s distribution timeline following approval. We, at SheMed, are working to add it to our programme. NHS access will require a separate NICE technology appraisal.

Can I take orforglipron if I’m on levothyroxine?

No specific interaction between Orforglipron and levothyroxine has been identified as Orforglipron has no food or water restrictions and can be taken at any time.  Women on levothyroxine should discuss their full medication list with their prescriber before starting.

‍

Sources and Further Reading

1. MHRA GOV.UK – UK First in Europe to Authorise Orforglipron (10 August 2026)

2. FDA Prescribing Information – Foundayo (Orforglipron) Full Label (2026)

3. DailyMed – Foundayo (Orforglipron) Label

4. NEJM – ATTAIN-1: Orforglipron for Obesity (Wharton S et al., 2025)

5. Drugs.com – Foundayo (Orforglipron) Approval History, Dosing and Side Effects

6. DrugBank – Orforglipron: Chemistry and Development Background

7. Mayo Clinic – Orforglipron Drug Description

8. The Pharmaceutical Journal – MHRA Approves Orforglipron (10 August 2026)

‍